AIDAN asks DCGI to withdraw approval for Bharat Biotech's Covaxin

The All India Drug Action Network (AIDAN) has urged the DCGI to reconsider the recommendations of the SEC in granting the REU approval to COVAXIN. The AIDAN has said it is shocked to learn about the recommendation to grant REU approval to Bharat Biotech's COVAXIN in "clinical trial mode" and "specially in the context of infection by mutant strains".

from IndiaTV India: Google News Feed https://ift.tt/3o8d5Y4

Get Breaking news, Live news, and latest news from India and around the world on INDILIVENEWS.com, which are in the interest of nation and humanity. Like us on Facebook or Follow us on Twitter and Reddit for the latest news blog and live news update

Trending News